Atlas Trials

Celldex Therapeutics

45 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Celldex Therapeutics

RecordFirmDate
A Study of CDX-622 in Participants With Mild to Moderate Asthma (NCT07330778)Celldex Therapeutics2026-06-01
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) (NCT07266402)Celldex Therapeutics2026-01-15
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (NCT07256392)Celldex Therapeutics2025-11-25
A Study of Barzolvolimab in Patients With Atopic Dermatitis (NCT06727552)Celldex Therapeutics2024-12-18
A Phase I Study of CDX-622 (NCT06650761)Celldex Therapeutics2024-11-01
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (NCT06455202)Celldex Therapeutics2024-07-19
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (NCT06445023)Celldex Therapeutics2024-07-11
A Study of Barzolvolimab in Patients With Prurigo Nodularis (NCT06366750)Celldex Therapeutics2024-04-12
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (NCT05774184)Celldex Therapeutics2023-06-01
A Study of CDX-585 in Patients With Advanced Malignancies (NCT05788484)Celldex Therapeutics2023-05-11
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria (NCT05405660)Celldex Therapeutics2022-06-28
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria (NCT05368285)Celldex Therapeutics2022-05-19
A Study of CDX-0159 in Patients With Prurigo Nodularis (NCT04944862)Celldex Therapeutics2021-11-08
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects (NCT05031624)Celldex Therapeutics2021-08-30
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria (NCT04548869)Celldex Therapeutics2020-11-24
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria (NCT04538794)Celldex Therapeutics2020-09-24
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943)Celldex Therapeutics2020-08-04
A Phase 1 Study of CDX-0159 (NCT04146129)Celldex Therapeutics2019-10-29
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma (NCT03254927)Celldex Therapeutics2018-03-27
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950)Celldex Therapeutics2017-12-01

Track Celldex Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.